<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01183364</url>
  </required_header>
  <id_info>
    <org_study_id>9090-07</org_study_id>
    <nct_id>NCT01183364</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors</brief_title>
  <official_title>A Phase 1, Pharmacokinetic Study of STA-9090 in Combination With Docetaxel in Subjects With Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synta Pharmaceuticals Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Synta Pharmaceuticals Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 1, dose-escalation study to determine the recommended doses of&#xD;
      STA-9090 (ganetespib) and docetaxel for the treatment of subjects with solid tumor&#xD;
      malignancies. The safety and tolerability of the treatment will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of STA-9090 (ganetespib) and docetaxel combination</measure>
    <time_frame>June 2011</time_frame>
    <description>The number of adverse events will be used as a measure of safety</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>June 2011</time_frame>
    <description>Pharmacokinetics of STA-9090 (ganetespib) and Docetaxel. This includes concentrations of these drugs in patients' blood at various protocol-specified times relative to the time of dose administration. These will be summarized by parameters including maximum concentration, total exposure and how fast the patient's body gets rid of the drug (known as Cmax, AUC, t1/2, respectively).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Solid Tumor Malignancies</condition>
  <arm_group>
    <arm_group_label>STA-9090 and Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STA-9090 (ganetespib) and Docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STA-9090 (ganetespib) with Docetaxel</intervention_name>
    <description>One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.</description>
    <arm_group_label>STA-9090 and Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have histologically confirmed metastatic or unresectable malignancy with evidence&#xD;
             of progression&#xD;
&#xD;
          -  If subject has been treated with docetaxel, must have evidence of persistent or&#xD;
             progressive disease&#xD;
&#xD;
          -  Measurable disease per RECIST&#xD;
&#xD;
          -  CNS metastases are permitted if treated and radiographically and clinically stable for&#xD;
             4 weeks prior to first dose&#xD;
&#xD;
          -  ECOG status less than or equal to 2&#xD;
&#xD;
          -  Life expectancy greater than 3 months&#xD;
&#xD;
          -  Adequate hematological, hepatic and renal function as defined by protocol&#xD;
&#xD;
          -  Willingness and ability to comply with study requirements&#xD;
&#xD;
          -  Female subjects of childbearing age must have a negative pregnancy test at study entry&#xD;
&#xD;
          -  Female subjects of child bearing age and males must agree to use adequate&#xD;
             contraception as defined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy or investigational agents within 3 weeks or 5 times the agent's&#xD;
             half life, whichever is shorter prior to first dose&#xD;
&#xD;
          -  Radiotherapy within 2 weeks of first dose&#xD;
&#xD;
          -  Surgery, radiotherapy or ablative procedure to the only area of measurable disease&#xD;
&#xD;
          -  Major surgery within 4 weeks of first dose&#xD;
&#xD;
          -  Poor venous access that would require an indwelling catheter for study drug&#xD;
             administration&#xD;
&#xD;
          -  History of severe allergic or hypersensitivity reactions to STA-9090 or docetaxel or&#xD;
             their diluents or excipients&#xD;
&#xD;
          -  Baseline QTc &gt;470 msec or previous history of QT prolongation while taking other&#xD;
             medications&#xD;
&#xD;
          -  Peripheral neuropathy &gt; Grade 1&#xD;
&#xD;
          -  Ventricular ejection fraction less than or equal to 55% at baseline&#xD;
&#xD;
          -  Treatment with chronic immunosuppressants. However subjects may receive steroids for&#xD;
             stable CNS metastases&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor malignancies</keyword>
  <keyword>tumor</keyword>
  <keyword>cancer</keyword>
  <keyword>STA-9090</keyword>
  <keyword>ganetespib</keyword>
  <keyword>HSP90 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

